Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy.
BACKGROUND
The precise mechanisms involved in the initiation and progression of rheumatoid arthritis (RA) are not known. Early stages of RA often have non-specific symptoms, delaying diagnosis and therapy. Additionally, there are currently no established means to predict clinical responsiveness to therapy. Immune cell activation is a critical component therefore we examined the cellular activation of peripheral blood mononuclear cells (PBMCs) in the early stages of RA, in order to develop a novel diagnostic modality.


RESULTS
PBMCs were isolated from individuals diagnosed with early RA (ERA) (n = 38), longstanding RA (n = 10), osteoarthritis (OA) (n = 19) and from healthy individuals (n = 10). PBMCs were examined for activation of 15 signaling effectors, using phosphorylation status as a measure of activation in immunophenotyped cells, by flow cytometry (phospho-flow). CD3+CD4+, CD3+CD8+ and CD20+ cells isolated from patients with ERA, RA and OA exhibited activation of multiple phospho-epitopes. ERA patient PBMCs showed a bias towards phosphorylation-activation in the CD4+ and CD20+ compartments compared to OA PBMCs, where phospho-activation was primarily observed in CD8+ cells. The ratio of phospho (p)-AKT/p-p38 was significantly elevated in patients with ERA and may have diagnostic potential. The mean fluorescent intensity (MFI) levels for p-AKT and p-H3 in CD4+, CD8+ and CD20+ T cells correlated directly with physician global assessment scores (MDGA) and DAS (disease activity score). Stratification by medications revealed that patients receiving leflunomide, systemic steroids or anti-TNF therapy had significant reductions in phospho-specific activation compared with patients not receiving these therapies. Correlative trends between medication-associated reductions in the levels of phosphorylation of specific signaling effectors and lower disease activity were observed.


CONCLUSIONS
Phospho-flow analysis identified phosphorylation-activation of specific signaling effectors in the PB from patients with ERA. Notably, phosphorylation of these signaling effectors did not distinguish ERA from late RA, suggesting that the activation status of discrete cell populations is already established early in disease. However, when the ratio of MFI values for p-AKT and p-p38 is >1.5, there is a high likelihood of having a diagnosis of RA. Our results suggest that longitudinal sampling of patients undergoing therapy may result in phospho-signatures that are predictive of drug responsiveness.
Galligan
Carole L
CL
Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada.
Siebert
Janet C
JC
Siminovitch
Katherine A
KA
Keystone
Edward C
EC
Bykerk
Vivian
V
Perez
Omar D
OD
Fish
Eleanor N
EN
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016903:Drug Monitoring; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology*; D008297:Male; D010766:Phosphorylation
J Pharmacol Exp Ther. 1995 Nov;275(2):1043-9
7473131
Rheum Dis Clin North Am. 2001 May;27(2):269-81
11396092
Nat Chem Biol. 2008 Feb;4(2):132-42
18157122
Clin Exp Rheumatol. 2005 Mar-Apr;23(2):243-6
15895898
Transplantation. 1996 Jan 15;61(1):140-5
8560553
J Immunol. 1999 Feb 15;162(4):2095-102
9973483
J Exp Med. 2008 Jul 7;205(7):1543-50
18591412
Arthritis Res Ther. 2008;10(6):R147
19099567
Arthritis Rheum. 2005 Nov;52(11):3381-90
16258899
Lancet. 1998 Nov 7;352(9139):1498-504
9820297
J Immunol. 2008 May 1;180(9):6070-6
18424728
Cytometry A. 2003 Oct;55(2):61-70
14505311
N Engl J Med. 2000 Nov 30;343(22):1586-93
11096165
Clin Rheumatol. 2009 Jan;28(1):17-21
18663553
Transplantation. 1993 Jun;55(6):1361-6
8390735
Arthritis Rheum. 2009 Jun;60(6):1647-56
19479869
Rheumatology (Oxford). 2003 Feb;42(2):268-75
12595621
Arthritis Res Ther. 2005;7(4):R784-95
15987480
J Clin Invest. 1994 Aug;94(2):749-60
8040330
Cell. 2004 Jul 23;118(2):217-28
15260991
J Immunol. 2000 Apr 1;164(7):3894-901
10725752
J Rheumatol Suppl. 2007 Nov;80:1-7
17985417
Ann Rheum Dis. 2004 Sep;63(9):1090-5
15308518
Arthritis Res Ther. 2008;10 Suppl 1:S5
19007425
Arthritis Rheum. 2000 Nov;43(11):2501-12
11083274
Transplantation. 1996 Feb 27;61(4):635-42
8610393
Arthritis Rheum. 2000 Feb;43(2):464-5
10693890
Arthritis Rheum. 2004 Mar;50(3):794-804
15022321
Lancet. 2001 Sep 15;358(9285):903-11
11567728
J Virol. 2007 Aug;81(15):7860-72
17522202
Blood. 2007 Mar 15;109(6):2589-96
17105820
Rheumatology (Oxford). 2003 Jan;42(1):89-96
12509619
J Rheumatol. 2007 Nov;34(11):2285-90
17937463
Bull NYU Hosp Jt Dis. 2007;65(3):168-73
17922664
Mol Immunol. 2004 Jul;41(6-7):687-700
15220004
J Clin Rheumatol. 2005 Jun;11(3 Suppl):S39-44
16357749
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S65-70
14969053
J Immunol. 2008 Jul 15;181(2):1190-8
18606672
Arthritis Rheum. 2008 Aug;58(8):2241-7
18668546
N Engl J Med. 2005 Sep 15;353(11):1114-23
16162882
Arthritis Rheum. 2007 May;56(5):1424-32
17469099
Curr Opin Investig Drugs. 2003 May;4(5):572-7
12833651
Arthritis Rheum. 1988 Mar;31(3):315-24
3358796
Ann Rheum Dis. 2006 Dec;65(12):1558-64
16760256
Ann Rheum Dis. 2009 Oct;68(10):1644-50
18957484
Br Med Bull. 1995 Apr;51(2):286-95
7552064
Ann Rheum Dis. 2005 Aug;64(8):1199-204
15640269
Methods Mol Biol. 2004;263:67-94
14976361
Arthritis Rheum. 1994 Apr;37(4):481-94
8147925
Clin Immunol. 2004 Mar;110(3):206-21
15047199
Clin Exp Immunol. 2008 May;152(2):372-80
18341611
J Rheumatol. 2001 Aug;28(8):1793-9
11508581
Ann Rheum Dis. 2003 Feb;62(2):120-6
12525380
Biomed Pharmacother. 2006 Dec;60(10):648-55
17064873
N Engl J Med. 2004 Jun 17;350(25):2572-81
15201414
Ann Rheum Dis. 2009 Jul;68(7):1184-91
18728049
J Immunol. 2007 Mar 15;178(6):3427-36
17339437
Ann Rheum Dis. 2009 Sep;68(9):1482-5
19015211
J Immunol. 1998 Feb 15;160(4):1581-8
9469413
J Immunol. 2001 Oct 15;167(8):4710-8
11591802
J Clin Invest. 1995 Sep;96(3):1631-8
7657832
Arthritis Rheum. 2002 Nov;46(11):2847-56
12428224
Ann Rheum Dis. 2003 May;62(5):440-3
12695157
J Cell Sci. 2003 Sep 15;116(Pt 18):3677-85
12917355
Arthritis Rheum. 2000 Jan;43(1):22-9
10643696
Cell Immunol. 1992 Oct 15;144(2):347-57
1356636
Ann N Y Acad Sci. 2008 Nov;1143:268-85
19076355
Rheumatology (Oxford). 2008 Apr;47(4):399-402
18263596
Ann Rheum Dis. 1997 Jan;56(1):27-31
9059137
Ann Rheum Dis. 2005 Jan;64(1):38-43
15130899
Nat Methods. 2006 May;3(5):361-8
16628206
Science. 1995 Oct 13;270(5234):286-90
7569976
Bull NYU Hosp Jt Dis. 2008;66(3):210-5
18937634